Journal article 992 views 226 downloads
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
Mansoor Husain,
Steve Bain 
,
Ole K. Jeppesen,
Ildiko Lingvay,
Rasmus Sørrig,
Marianne B. Treppendahl,
Tina Vilsbøll
,
Ole K. Jeppesen,
Ildiko Lingvay,
Rasmus Sørrig,
Marianne B. Treppendahl,
Tina Vilsbøll
Diabetes, Obesity and Metabolism, Volume: 22, Issue: 3, Pages: 442 - 451
Swansea University Author:
Steve Bain
-
PDF | Version of Record
Released under the terms of a Creative Commons Attribution-NonCommercial License (CC-BY-NC).
Download (950.96KB)
DOI (Published version): 10.1111/dom.13955
Abstract
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
| Published in: | Diabetes, Obesity and Metabolism |
|---|---|
| ISSN: | 1462-8902 1463-1326 |
| Published: |
Wiley
2020
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa53094 |
| Keywords: |
cardiovascular disease, clinical trial, glucagon-like peptide-1 analogue, phase III study, type 2 diabetes |
|---|---|
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
3 |
| Start Page: |
442 |
| End Page: |
451 |